Health Care·Biotechnology·$6.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.36 | N/A | N/A |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management emphasized the importance of ongoing clinical trials. There was no specific guidance provided for future earnings or revenue.
Management did not provide specific revenue guidance for the upcoming quarters.
The focus remains on advancing clinical trials and product development.
The earnings report reflects ongoing challenges for Protagonist Therapeutics, particularly with EPS falling short of expectations. Despite this, the stock rose by 1.57%, likely driven by investor optimism about the company's clinical development efforts. The lack of revenue data and guidance suggests uncertainty in the near term, but the market seems to remain hopeful about future advancements.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NUTRIEN LTD
May 7, 2018